DigestRedComo funciona
Red
/
Empresas
Ju
No verificado

Junshi Biosciences

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

19 Comunicados de prensa

Ver todos los comunicados de prensa
13/03/2026
Biotecnología
Gestión empresarial/Administración de Empresas
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
09/03/2026
Biotecnología
Anuncios breves
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
24/02/2026
Biotecnología
Gestión empresarial/Administración de Empresas
Medicina Salud Bienestar
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
05/12/2025
Biotecnología
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
05/12/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
24/11/2025
Biotecnología
Medicina Salud Bienestar
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
16/10/2025
Biotecnología
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
07/09/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
26/08/2025
Biotecnología
Gestión empresarial/Administración de Empresas
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0
08/08/2025
Biotecnología
Medicina Salud Bienestar
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
Fuente
Junshi Biosciences
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0